Clinical Trials Logo

Ototoxicity clinical trials

View clinical trials related to Ototoxicity.

Filter by:

NCT ID: NCT01624324 Recruiting - Ototoxicity Clinical Trials

Aminoglycoside Plasma Level Measurement in Neonates With Infection

Start date: November 2010
Phase: N/A
Study type: Observational

The aim of this study is to determine whether the plasma concentration of aminoglycoside in Indonesia neonates with infection are within safe and effective range and its association with cochlear toxicity and nephrotoxicity.

NCT ID: NCT01451853 Not yet recruiting - Lung Cancer Clinical Trials

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Start date: January 15, 2018
Phase: Phase 2
Study type: Interventional

Chemotherapy treatment with platinum based agents is well noted to cause ototoxicity. It is the objective of this study to determine the safety and efficacy of SPI-1005 at three dose levels when delivered orally twice daily for 3 days, surrounding each cycle of platinum chemotherapy in head and neck or non-small cell lung cancer patients to prevent and treat chemotherapy induced hearing loss and tinnitus.

NCT ID: NCT01285674 Not yet recruiting - Ototoxicity Clinical Trials

Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin.

Start date: January 2011
Phase: N/A
Study type: Interventional

In this study we will aim to determine if cisplatin ototoxicity can be prevented by intratympanic administration of corticosteroids.

NCT ID: NCT01263262 Completed - Clinical trials for Surgical Site Infection

A Comparison of Infection Rates Between Two Surgical Sites

Start date: January 2011
Phase: N/A
Study type: Observational

Does the use of chlorhexidine scrub prior to cutaneous surgery on the face increase the chances of toxicity to the eyes or ears? In addition, does the us eof chlorhexidine scrub on the face prior to cutaneous surgery decrease the chances of a post-operative wound infection?

NCT ID: NCT01216800 Recruiting - Clinical trials for Head and Neck Cancer

Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors

Start date: August 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy is more effective in decreasing hearing loss in patients undergoing radiation therapy for parotid gland cancer. PURPOSE: This randomized phase III trial is studying intensity-modulated radiation therapy to see how well it works compared with 3-dimensional conformal radiation therapy in decreasing hearing loss in patients who have undergone surgery for parotid tumors.

NCT ID: NCT01139281 Completed - Hearing Loss Clinical Trials

The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans

Start date: June 2007
Phase: Phase 2
Study type: Interventional

The proposal of this study was to evaluate in human beings, using distortion product otoacoustic emission (DPOAE) test, the action of ginkgo biloba extract (GBE761)as a possible ear protective against cisplatin (CDDP) induced hearing loss.

NCT ID: NCT00716976 Completed - Ovarian Cancer Clinical Trials

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Start date: June 23, 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing hearing loss. PURPOSE: This randomized phase III trial is studying sodium thiosulfate to see how well it works in preventing hearing loss in young patients receiving cisplatin for newly diagnosed germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy.

NCT ID: NCT00683319 Active, not recruiting - Clinical trials for Brain and Central Nervous System Tumors

Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy

Start date: April 2008
Phase: Phase 3
Study type: Observational

RATIONALE: Gathering information about how young patients with ependymoma respond to standard combination chemotherapy and learning about the long-term effects of this treatment may help doctors plan better treatment. PURPOSE: This phase III trial is observing young patients with ependymoma undergoing standard combination chemotherapy.

NCT ID: NCT00652132 Completed - Liver Cancer Clinical Trials

Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer

SIOPEL6
Start date: December 15, 2007
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as sodium thiosulfate, may protect normal cells from the side effects of chemotherapy. It is not yet known whether giving sodium thiosulfate is effective in reducing hearing damage caused by cisplatin in treating young patients with liver cancer. PURPOSE: This randomized phase III trial is studying how well sodium thiosulfate works to decrease hearing loss caused by cisplatin in treating young patients with stage I, stage II, or stage III childhood liver cancer.

NCT ID: NCT00578760 Not yet recruiting - Hearing Loss Clinical Trials

Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?

Start date: February 2008
Phase: N/A
Study type: Interventional

Aspirin (ASA) has been shown, in an animal model, to attenuate the ototoxic properties of cisplatin. The researchers plan to investigate this in patients undergoing cisplatin chemotherapy. The researchers hypothesise that low-dose aspirin can prevent cisplatin induced ototoxicity in the clinical setting.